Study of MRM-3379 in Male Participants With Fragile X Syndrome

Recruiting

Phase 2

MRM-3379Study of MRM-3379 in Male Participants With Fragile X Syndrome

Sponsor:

Mirum Pharmaceuticals, Inc.

Code:

NCT07209462

Conditions

Fragile X Syndrome

Eligibility Criteria

Sex: Male

Age: 13 - 45

Healthy Volunteers: Not accepted

Interventions

Low dose of MRM-3379

Middle Dose of MRM-3379

High dose of MRM-3379

Placebo

Low dose of MRM-3379 Open-Label

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-06. This information was provided to ClinicalTrials.gov by Mirum Pharmaceuticals, Inc. on 2025-10-24.